2016-02-11T16:54:26-06:00 2015-06-30 941254756 HOOD & STRONG LLP 100 FIRST STREET 14TH FLOOR SAN FRANCISCO CA 94105 990 2014-07-01 030485196 MYELIN REPAIR FOUNDATION MYEL 4088712410 20111 EDINBURGH DRIVE SARATOGA CA 95070 DENISE ST ONGE CFO 4088712410 2016-02-10 1 MAGA E KISRIEV P01008919 4157810793 2014 2016-04-25 22:37:26Z X SCOTT JOHNSON 20111 EDINBURGH DRIVE SARATOGA CA 95070 2773069 0 X WWW.MYELINREPAIR.ORG X 2002 CA ACCELERATING THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MS. 6 5 19 20 0 0 3463318 2660020 0 0 -3087 -10708 21665 106579 3481896 2755891 1648750 393504 0 0 2633342 1961438 0 0 646430 2004071 3269868 6286163 5624810 -2804267 -2868919 4343784 1355841 405300 281806 3938484 1074035 X TO ACCELERATE THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MULTIPLE SCLEROSIS. THE MRF DRIVES BASIC RESEARCH, TRANSLATES DISCOVERIES AND PARTNERS WITH COMPANIES AND GOVERNMENT TO ENSURE TREATMENTS GET RAPIDLY TO PATIENTS. 0 0 2123366 393504 0 DISCOVERY BIOLOGY: MRF MAINTAINED ITS DISCOVERY BIOLOGY EFFORTS BY MANAGING AND INITIALLY FUNDING A WORLDWIDE CONSORTIUM OF OVER 50 RESEARCHERS. DUE TO THIS YEAR'S BUDGET LIMITATIONS ONLY PARTIAL FUNDS WERE PROVIDED TO EACH CONSORTIUM LAB. DESPITE THIS, MRF CONTINUED TO CONDUCT MONTHLY COLLABORATION MEETINGS WITH MRF'S ACADEMIC AND SCIENTIFIC CONSORTIUM TO FOSTER RESEARCH AND PROVIDE GUIDANCE TOWARDS DEVELOPMENT OF MYELIN REPAIR THERAPEUTICS. BEGINNING JULY 1, 2015, MRF IS NO LONGER ABLE TO FUND CONSORTIUM LABS DUE TO LACK OF MRF FUNDING. HOWEVER, MRF WILL HOLD ITS NEXT ANNUAL COLLABORATIVE RESEARCH MEETING IN NOVEMBER 2015 AFTER WHICH MRF WILL EVALUATE THE MEETING'S SUCCESS AND DETERMINE IF MRF CAN AND SHOULD CONTINUE TO CONDUCT SUCH MEETINGS IN 2016 AND BEYOND.TRANSLATIONAL MEDICINE: MRF INCREASED THE CAPACITY AND RELIABILITY OF OLIGODENDROCYTE DIFFERENTIATION AND SIGNIFICANTLY MODIFIED AND IMPROVED ITS MYELINATION ASSAYS AS WELL AS ADDED AND OPTIMIZED A HIGH-CAPACITY OLIGODENDROCYTE PROTECTION ASSAY AND INITIATED DEVELOPMENT OF AN IN VIVO MYELINATION ASSAY. THE NATIONAL INSTITUTES OF HEALTH CLINICAL COLLECTION OF OVER 700 COMPOUNDS WERE SCREENED IN BOTH THE PROTECTION AND NEWER VERSIONS OF THE MYELINATION ASSAY. OVER A DOZEN "HITS" WERE IDENTIFIED AND ARE BEING FURTHER EVALUATED FOR POTENTIAL MYELIN REPAIR THERAPEUTICS. MRF NOW HAS A SUITE OF FOUR ASSAYS AVAILABLE WHICH FACILITATED THE ADDITION OF TWO NEW PARTNERSHIPS/COLLABORATIONS AND PROGRESS OF MRF'S INTERNAL DRUG DISCOVERY EFFORTS. A LEGACY STRATEGY WAS ALSO IMPLEMENTED TO PROVIDE THE PROTOCOLS FOR THESE ASSAYS TO ANY ORGANIZATION THAT WANTS THEM (AT LEAST TWO HAVE ACCEPTED THUS FAR). IN ADDITION, A PAPER THAT DESCRIBES MRF'S SCREENING EFFORTS AND PROVIDES PROTOCOLS HAS BEEN WRITTEN AND WAS SUBMITTED FOR PUBLICATION IN SEPTEMBER 2015. CLINICAL: MRF'S EFFORTS CONTINUED WITH THE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) ESTABLISHED IN 2014 BETWEEN THE NATIONAL INSTITUTES OF HEALTH (NIH) AND MRF TO CONDUCT PHASE I AND PHASE II OF A HUMAN CLINICAL TRIAL CLINICAL OF MRF-008. MRF'S EFFORTS FOCUSED ON THE MANUFACTURE AND IMPORTATION OF THE MRF-008 REQUISITE DRUG (GUANABENZ), FORMULATION INTO CAPSULES, CLINICAL PLANNING AND PREPARATION TO INITIATE THE CLINICAL TRIAL. PHASE I OF THE CLINICAL TRIAL BEGAN IN SEPTEMBER 2015. IN APRIL 2016, MRF WILL PROVIDE THE REMAINING FUNDING TO THE NIH FOR PHASE II OF THE CLINICAL TRIAL. 2123366 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 30 0 1 19 1 0 0 0 0 0 1 1 0 0 0 0 0 X 6 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X MARY LACHNIT 4088712410 20111 EDINBURGH DRIVE SARATOGA CA 95070 SHARON WIENBAR BOARD MEMBER 1.00 X 0 0 0 CASEY MCGLYNN BOARD MEMBER 1.00 X 0 0 0 BOBBY MEHTA BOARD MEMBER 1.00 X 0 0 0 ANDY CATES BOARD MEMBER 1.00 X 0 0 0 JIM GIDWITZ BOARD MEMBER 1.00 X 0 0 0 SCOTT JOHNSON CEO 40.00 X X 290770 0 72402 JAY TUNG VP DRUG DISCOVERY 40.00 X 234194 0 37163 DENISE ST ONGE CFO 10.00 X 51450 0 0 TASSIE COLLINS DIRECTOR 40.00 X 187775 0 19928 JASON DUGAS ASSOCIATE DIRECTOR (THRU 12/31/14) 40.00 X 136608 0 17210 ELEN ROSLER SCIENTIST 40.00 X 106575 0 11002 KAREN LARIOSA SCIENTIST 40.00 X 106080 0 68 1113452 0 157773 8 0 1 0 0 2660020 2204 2660020 392 392 2940 3138 3092 14086 -152 -10948 -11100 -11100 REIMBURSED LEGAL FEES 900099 106539 106539 OTHER INCOME 900099 40 40 106579 2755891 0 0 95871 393504 393504 876848 640770 66981 169097 809278 345977 174711 288590 135544 45406 50306 39832 139768 81934 19740 38094 34050 34050 22660 22660 68940 49573 4879 14488 15416 15416 20207 7610 6776 5821 53019 20441 6361 26217 304553 228986 40538 35029 23366 3585 12634 7147 1445 1445 21265 14549 3616 3100 24174 17215 3360 3599 PLEDGE RECEIVABLE WRITE 2408402 2408402 ANNUAL RESEARCH MEETING 93150 93150 TRANSLATIONAL MEDICINE 83043 83043 DRUG TARGET VALIDATION 60198 60198 35980 35980 5624810 2123366 2855014 646430 1618879 801925 2540712 450000 63200 20510 79526 39031 66583 40495 54410 42911 4343784 1355841 405300 205448 76358 405300 281806 X 1397772 450000 2540712 624035 3938484 1074035 4343784 1355841 -2868919 4470 0 X 0 1 X 1 0 X 1528919 1761904 4428671 3463318 2660019 13842831 1528919 1761904 4428671 3463318 2660019 13842831 5265724 8577107 26870 7382 4420 1256 392 40320 23960 67204 19500 21665 106579 238908 14122059 0.60740 0.42740 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2010 AMOUNT: $ 23,960. 2011 AMOUNT: $ 67,204. 2012 AMOUNT: $ 19,500. 2013 AMOUNT: $ 21,665. 2014 AMOUNT: $ 40. REIMBURSED LEGAL FEES - 2010 AMOUNT: $ 0. 2011 AMOUNT: $ 0. 2012 AMOUNT: $ 0. 2013 AMOUNT: $ 0. 2014 AMOUNT: $ 106,539. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 53546 13051 40495 25980 25980 0 40495 X 2851714 4470 197892 202362 2649352 106539 106539 2755891 5716163 197892 197892 5518271 106539 106539 5624810 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME AND CALIFORNIA FRANCHISE TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND SECTION 23701D OF THE CALIFORNIA REVENUE AND TAXATION CODE, RESPECTIVELY. ADDITIONALLY, THE FOUNDATION HAS BEEN DETERMINED BY THE INTERNAL REVENUE SERVICE NOT TO BE A PRIVATE FOUNDATION WITHIN THE MEANING OF SECTION 509(A) OF THE INTERNAL REVENUE CODE. THE FOUNDATION FOLLOWS FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS CODIFICATION TOPIC 740 INCOME TAXES TO ACCOUNT FOR UNCERTAIN TAX POSITIONS. MANAGEMENT HAS CONCLUDED THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS GUIDANCE. THE FOUNDATION IS GENERALLY NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY FEDERAL TAX AUTHORITIES FOR TAX YEARS ENDING JUNE 10, 2011 AND BEFORE, AND BY CALIFORNIA AUTHORITIES FOR TAX YEARS ENDING JUNE 30, 2010 AND BEFORE PART XI, LINE 4B - OTHER ADJUSTMENTS: REIMBURSED LEGAL FEES NETTED AGAINST REVENUE 106,539. PART XII, LINE 4B - OTHER ADJUSTMENTS: REIMBURSED LEGAL FEES NETTED AGAINST REVENUE 106,539. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES EVOTEC SPONSORED RESEARCH 32963 0 0 0 0 0 0 32963 0 32963 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCHER IS SUBECT TO TERMS AND CONDITIONS OF THE SPONSORED RESEARCH AGREEMENT BETWEEN THE UNIVERSITY AND THE MRF. THE RESEARCHER'S WORK IS REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND BY THE MRF RESEARCH AND DEVELOPMENT STAFF. 1 NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DR CHICAGO IL 60611 362167817 501(C)(3) 125000 MYELIN RESEARCH STANFORD UNIVERSITY FAIRCHILD BLDG RM D201A STANFORD CA 94305 941156365 501(C)(3) 93504 MYELIN RESEARCH UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE CHICAGO IL 60637 362177139 501(C)(3) 175000 MYELIN RESEARCH 3 0 PART I, LINE 2: THE UNIVERSITY IS SUBJECT TO TERMS AND CONDITIONS OF THE CONSORTIUM AGREEMENT BETWEEN THE UNIVERSITY AND THE MRF. THE RESEARCHER'S WORK IS REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND BY THE MRF RESEARCH AND DEVELOPMENT STAFF. X 0 1 X X X X 0 0 0 0 0 0 0 0 0 SCOTT JOHNSON CEO 290770 0 0 0 0 0 0 0 72402 0 363172 0 0 0 JAY TUNG VP DRUG DISCOVERY 234194 0 0 0 0 0 0 0 37163 0 271357 0 0 0 TASSIE COLLINS DIRECTOR 187775 0 0 0 0 0 0 0 19928 0 207703 0 0 0 JASON DUGAS ASSOCIATE DIRECTOR (THRU 12/31/14) 136608 0 0 0 0 0 0 0 17210 0 153818 0 0 0 PART I, LINE 1A MR. JOHNSON HAS MULTIPLE SCLEROSIS AND REQUIRES ASSISTANCE WHEN HE TRAVELS. MRF PAYS FOR HIS WIFE TO ACCOMPANY HIM ON BUSINESS TRIPS. PART I, LINE 3 CEO COMPENSATION IS DETERMINED BY THE INDEPENDENT COMPENSATION COMMITTEE. KEY EMPLOYEES' COMPENSATION IS DETERMINED BY AN ANNUAL REVIEW OF THE EMPLOYEE AND AN ANNUAL REVIEW OF THEIR COMPENSATION BY THE CEO. THIS INFORMATION IS ALSO SHARED WITH THE INDEPENDENT COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION B, LINE 11 THE TAXPAYER'S ACCOUNTING FIRM FORWARDS THE FORM 990 TO THE CFO WHO THEN FORWARDS THE FORM 990 TO THE BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING THE FORM 990. BOARD MEMBERS ARE ENCOURAGED TO REVIEW THE FORM AND TO FORWARD THEIR QUESTIONS, IF ANY, TO THE CONTROLLER OR CFO. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DRECTORS AND KEY EMPLOYEES ARE COVERED. ANY AND ALL CONFLICTS ARE REVIEWED BY DISINTERESTED BOARD MEMBERS AND, IF NEEDED, BY LEGAL COUNSEL. PERSONS WITH A CONFLICT OF INTEREST WILL BE RESTRICTED FROM MAKING KEY DECISIONS FOR MRF AS THEY RELATE TO THE INTEREST UNLESS OTHERWISE APPROVED BY THE MAJORITY OF THE DISINTERESTED BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15 CEO COMPENSATION IS DETERMINED BY THE INDEPENDENT COMPENSATION COMMITTEE. KEY EMPLOYEES' COMPENSATION IS DETERMINED BY AN ANNUAL REVIEW OF THE EMPLOYEE AND AN ANNUAL REVIEW OF THEIR COMPENSATION BY THE CEO. THIS INFORMATION IS ALSO SHARED WITH THE INDEPENDENT COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE. GOVERNING DOCUMENTS AND POLICIES ARE AVAILABLE UPON REQUEST.